Personalized medicine for men with benign prostatic hyperplasia
This article has no abstract so we have provided the first paragraph of the full text.
The 
1-adrenoceptor (AR) antagonists tamsulosin hydrochloride and naftopidil, which are used to treat benign prostatic hyperplasia (BPH), are subtype-selective; tamsulosin preferentially binds the 1a-AR, whereas naftopidil preferentially binds the 1d-AR. Men with BPH seem to have either predominant 1a-AR or 1d-AR prostate-specific messenger RNA (mRNA) expression, and Kojima et al. have now examined whether this genetic difference explains the variation between patients' responses to treatment with subtype-selective 1-AR antagonists.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.